R&D News | pharmaphorum

News

MindMed gets FDA breakthrough tag for LSD in anxiety

In another inflection point for the psychedelic medicines category, Mind Medicine (MindMed) has claimed breakthrough status from the FDA for its LSD-based candidate MM120

News

Novo Nordisk’s oral amycretin tops Wegovy in obesity trial

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling

News

GSK scores again with Blenrep in multiple myeloma

GSK continues to build the case for its multiple myeloma therapy Blenrep, which was pulled from the US market last year, with another positive phase 3 trial.

News

HIV, the AIDS virus (yellow), infecting a human cell

Gilead and MSD say weekly oral therapy controls HIV

Reducing the burden of treatment for people with HIV has been a key objective for drug developers since antiretroviral therapy (ART) first reached the market.

News

Boundless Bio files IPO, and other biotech financings

Boundless Bio made a play to become the seventh US biotech to seek a public listing in 2024, ending a brief hiatus in IPO activity after a busy start to the year.

News

Novo Nordisk looks set to add another string to Ozempic bow

Novo Nordisk’s GLP-1 agonist Ozempic has shown efficacy in yet another indication, achieving a 24% reduction in kidney disease-related events in people with type 2 diabete

MindMed gets FDA breakthrough tag for LSD in anxiety

Novo Nordisk’s oral amycretin tops Wegovy in obesity trial

GSK scores again with Blenrep in multiple myeloma

Gilead and MSD say weekly oral therapy controls HIV

Boundless Bio files IPO, and other biotech financings

Novo Nordisk looks set to add another string to Ozempic bow

UK seeks views on indefinite CE marks for medical devices

How to meet your physicians where they are online

News

Editor's Picks